ShockWave Medical, Inc. (SWAV)
NASDAQ: SWAV · IEX Real-Time Price · USD
325.63
+3.02 (0.94%)
At close: Mar 28, 2024, 4:00 PM
324.99
-0.64 (-0.20%)
After-hours: Mar 28, 2024, 4:50 PM EDT

ShockWave Medical Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Revenue
730.23489.73237.1567.7942.9312.261.72
Revenue Growth (YoY)
49.11%106.51%249.83%57.92%250.05%613.38%-
Cost of Revenue
95.396541.4420.9917.167.252.84
Gross Profit
634.84424.74195.7146.825.775.01-1.12
Selling, General & Admin
330.1218.92146.0475.5444.7523.5211.79
Research & Development
145.6581.6850.5436.9332.8522.717.96
Operating Expenses
475.75300.6196.58112.4677.6146.2129.75
Operating Income
159.09124.13-0.87-65.66-51.84-41.2-30.87
Interest Expense / Income
6.911.891.11.210.940.40.06
Other Expense / Income
-22.091.426.87-1.26-1.74-0.54-0.33
Pretax Income
174.28120.83-8.84-65.62-51.05-41.06-30.59
Income Tax
27-95.170.30.080.060.040.03
Net Income
147.28216-9.14-65.7-51.11-41.1-30.62
Net Income Growth
-31.81%------
Shares Outstanding (Basic)
373635332422
Shares Outstanding (Diluted)
383835332422
Shares Change
0.86%7.93%6.07%38.42%1260.47%13.12%-
EPS (Basic)
4.016.02-0.26-1.99-2.14-23.39-19.71
EPS (Diluted)
3.855.70-0.26-1.99-2.14-23.39-19.71
EPS Growth
-32.46%------
Free Cash Flow
165.4692.612.6-82.7-51.92-43.45-30.77
Free Cash Flow Per Share
4.512.580.07-2.50-2.17-24.73-19.81
Gross Margin
86.94%86.73%82.53%69.03%60.03%40.88%-64.98%
Operating Margin
21.79%25.35%-0.37%-96.86%-120.76%-335.97%-1795.52%
Profit Margin
20.17%44.10%-3.85%-96.92%-119.06%-335.17%-1780.98%
Free Cash Flow Margin
22.66%18.91%1.10%-122.00%-120.96%-354.29%-1790.11%
Effective Tax Rate
15.49%-78.76%-----
EBITDA
194.7130.61-2.2-61.06-47.82-39.96-30.06
EBITDA Margin
26.66%26.67%-0.93%-90.08%-111.40%-325.88%-1748.87%
Depreciation & Amortization
13.527.95.543.352.280.70.47
EBIT
181.19122.71-7.74-64.41-50.1-40.66-30.53
EBIT Margin
24.81%25.06%-3.26%-95.01%-116.72%-331.59%-1776.09%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).